SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

	For the six months ended 30 June		
	2026	2025	Change
	RMB'Billion	*RMB'Billion*	*%*
Revenue	**19.44**	17.57	+10.6%
Profit attributable to owners of the parent			
As reported (Note 1)	**3.43**	3.39	+1.4%
Underlying profit (Note 2)	**3.34**	3.09	+8.1%
Underlying profit excluding dividend income from Sinovac LS (Note 2)	**3.34**	1.74	+92.3%
Sales of total innovative drugs and out-licensing	**8.79**	6.09	+44.3%
Share of revenue	**45.2%**	34.7%	
Sales of innovative drugs (Note 3)	**7.81**	6.05	+29.2%
Share of revenue	**40.2%**	34.4%	
Sales of out-license	**0.98**	0.04	+2,101.9%
Share of revenue	**5.0%**	0.3%	

The board of directors of the Company has declared the payment of an interim dividend of HK7 cents per share for the six months ended 30 June 2026.

Note 1: Profit attributable to owners of the parent as reported was prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRS"). The year-on-year increase in profit attributable to owners of the parent as reported was mainly driven by a notable growth in revenue and partially offset by the decrease in dividend income and fair value gain on investments during the period.

Note 2: Underlying profit attributable to owners of the parent is presented in this results announcement as an additional non-HKFRS financial measure to provide supplementary information for better assessment of the performance of the Group's core operations by excluding impacts of certain non-cash items and the share of profits and losses of associates and joint ventures, etc. A reconciliation between the profit attributable to owners of the parent as reported and the underlying profit attributable to owners of the parent has been set out under the section headed "Non-HKFRS Measure" of this announcement. The year-on-year growth in underlying profit attributable to owners of the parent was mainly driven by revenue growth and cost optimisation initiatives, partially offset by a decline in dividend income. Excluding dividend income from Sinovac LS, underlying profit significantly rose by RMB1.6 billion, representing an increase of 92.3% year-on-year.

Note 3: Sales is the gross sales amount minus the sales discount, innovative drugs are Class 1 or Class 2 national new drugs, excluding biosimilars, generic drugs and out-licensing.

CORPORATE PROFILE

Sino Biopharmaceutical Limited (the "Company" or "SBP Group", together with its subsidiaries, the "Group") is a leading, innovative R&D-driven pharmaceutical conglomerate in China. It prides itself on a fully-integrated industrial chain, covering drug R&D, intelligent production and commercial sales. Its products cover biopharmaceutical and chemical medicines enjoy an advantageous position in a host of four core therapeutic areas, namely oncology, liver/cardiometabolic diseases, respiratory/autoimmune and surgery/analgesia.

The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices– MSCI China Index, Hang Seng Index in 2018, and Hang Seng Connect Biotech 50 Index and Hang Seng China (Hong Kong-listed) 25 Index in 2020. It has been seven years in a row among the "Top 50 Global Pharmaceutical Enterprises" named by the US authoritative magazine Pharm Exec and was for three consecutive years among the "Asia's Fab 50 Companies" named by Forbes Asia.

The subsidiaries of the Group are located in Beijing, Shanghai, Nanjing, Lianyungang and multiple manufacturing sites. Since its inception, the Group has continued to boast outstanding achievements and robust growth. Its core member companies include Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("CT Tianqing"), Beijing Tide Pharmaceutical Co., Ltd. ("Beijing Tide"), LaNova Medicines Limited ("LaNova Medicines"), Hangzhou Hygieia Biomedical Co., Ltd. ("Hygieia"), Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTT"), Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. ("Chia Tai Qingjiang"), Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. ("Chia Tai Fenghai") and invoX Pharma Limited ("invoX").

SBP Group will continue to deliver its mission of "Science for a Healthier World" and focus on developing innovative therapies for patients. It is committed to becoming a world-leading pharmaceutical company.

CHAIRWOMAN'S STATEMENT

In March 2026, the Group officially changed its English stock short name to "SBP Group", with SBP representing Science, Breakthroughs and Patients. The new branding is a significant step forward in the Group's internationalization strategy and marks the beginning of a new phase of development. Over the past decade, the Group has successfully transformed itself into one of China's leading innovative pharmaceutical companies. Looking ahead to the next decade, the Group will focus on internationalization and strive to evolve into a global innovative pharmaceutical company that is guided by science, driven by breakthrough innovation and dedicated to benefiting patients worldwide. Committed to its mission of "Science for a Healthier World," the Group focuses on providing patients with more treatment options through innovative technologies, and creating sustainable long-term value for shareholders.

In 2026, the Group successively entered into major strategic cooperations bridging the global and China markets with leading global multinational pharmaceutical companies (MNCs) such as Sanofi, GlaxoSmithKline and AstraZeneca. The Group also fully embraces artificial intelligence (AI), and actively advances the integration of AI deeply across the entire industrial chain. By achieving breakthroughs in AI-driven drug discovery, the Group seeks to accelerate value creation and deliver more effective therapies to patients around the world with higher efficiency.

I. Innovation and R&D: Entering the Harvest Period, with Blockbuster Products Driving Performance Growth

Benefiting from years of continuous investment in R&D, the Group has officially entered a harvest period of innovative drugs approval. To date, the Group has cumulatively obtained approval for marketing for 20 national category 1 or category 2 innovative drugs, and for 8 biosimilars. With industry-leading efficiency in translating innovation into commercial success, the Group has delivered double-digit revenue growth for many years in a row, significantly outpacing the industry average.

Looking forward to the future, the Group's innovative pipeline will experience a new round of explosive growth. It is expected that nearly 30 national category 1 innovative drugs will be approved for marketing from 2026 to 2030, covering multiple blockbuster products with global first-in-class (FIC) or best-in-class (BIC) potential, which will serve as the core engine driving its performance growth. The Group will continue to focus on four core therapeutic areas: oncology, liver/cardiometabolic diseases, respiratory/autoimmune diseases, and surgery/analgesia, and enhance its innovative R&D capabilities at the very source to drive steady growth in its results.

II. Strategic M&A: Integrating Global High-Quality Resources to Comprehensively Strengthen R&D Capabilities

Strategic mergers and acquisitions is a key path for the Group to integrate industrial resources, complement its technological platforms, broaden its therapeutic layout, and enhance its core competitiveness. As for the two trillion-dollar markets of oncology and chronic diseases, the Group successively completed full acquisition of two biotech firms, namely, LaNova Medicines and Hygieia. In July 2025, the acquisition of LaNova Medicines has brought world-leading antibody discovery and ADC technology platforms to the Group, further strengthening the strategic positioning of the Group in next-generation oncology drugs. In January 2026, the acquisition of Hygieia has brought to the Group the world's first clinically validated liver-targeted small molecule interfering ribonucleic acid (siRNA) delivery platform capable of ultra long-acting administration with a "once-yearly" dosing regimen, along with dual-target, neurological and other cutting-edge siRNA delivery technologies.

By effectively integrating high-quality industrial resources in China, the Group will continue to advance the development of innovative drug molecules with global business potential, actively recruit leading scientific talents, and steadily build an innovative product portfolio with international competitiveness, bringing more breakthrough treatment options to patients around the world.

III. Globalization: Synergy of "Bringing in" and "Going out" Approach and Unlocking its Second Growth Driver

Leveraging its deep-rooted presence and leading position in China market, the Group accelerates the globalization strategy, adhering to the two-way approach of "bringing in" and "going out". In March 2026, the Group established licensing collaboration with Sanofi regarding Rovadicitinib, entitling the Group to a maximum payment of US$1.53 billion, as well as up to double-digit royalties based on net sales. In July 2026, the Group established licensing collaboration with AstraZeneca regarding TQC3721, entitling the Group to a maximum payment of US$1.9 billion, as well as double-digit royalties based on the annual net sales. In May and July 2026, the Group entered into strategic cooperation with GlaxoSmithKline twice, successively securing the commercialisation rights in mainland China for bepirovirsen, a blockbuster product in the field of liver disease, and two blockbuster respiratory products, namely, Trelegy Ellipta® and Anoro Ellipta®. The sales revenue from these three products in mainland China will be recognised as the Group's operating revenue.

Since 2026, out-licensing collaboration has become another major revenue stream for the Group, injecting strong momentum into its growth and paving the way for a second rising curve supported by international revenue. The Group will continue to explore diversified collaboration models with innovative pharmaceutical companies worldwide, broaden its international development pathway and create greater value for its long-term growth.

Looking forward to the coming decade, Sino Biopharmaceutical Limited will accelerate the launch of innovative drugs in countries and regions under its globalization strategy, and deliver the benefits of healthcare science to a broader global patient population.

Industry Overview

As the policy support for pharmaceutical innovation continues to intensify, China's pharmaceutical industry is accelerating its momentum and transitioning to a new development phase defined by first-in-class innovation and high-quality. In the first half of 2026, China introduced and implemented a series of systematic and targeted policies, designed to foster an innovation ecosystem spanning the full chain of R&D, regulatory review, reimbursement, and clinical application.

I. Industry Policy: Accelerated Development of a Full-Chain Support System

The sector's positioning achieved historic leap forward. In March 2026, the State Council's "Government Work Report" explicitly designated the biopharmaceutical sector as a national "emerging pillar industry" for the first time, placing it on par with integrated circuits, aerospace, low-altitude economy, new energy storage technologies and intelligent robotics. This marks a historic elevation for the biopharmaceutical sector in policy terms, from a "strategic emerging industry" to an "emerging pillar industry". The biopharmaceutical sector has been formally entrusted with the important strategic mission of driving economic growth, strengthening scientific and technological capabilities, and enhancing international competitiveness. It will receive higher-level policy focus and resource allocation, making the sector's medium- to long-term development prospects even more promising.

Pricing mechanisms set to undergo reform and optimisation. In April 2026, the General Office of the State Council issued the "Guidelines on Improving the Drug Price Formation Mechanism", proposing to optimise the initial pricing mechanism for newly launched medicines, including innovative drugs. For high-quality innovative drugs characterised by a high degree of innovation and significant clinical value, the policy supports pricing that are commensurate with its high cost and risk in the early stage of marketing, and maintaining the relative price stability for a certain period. This policy established, for the first time at the institutional level, a reasonable pricing range for high-value innovative drugs, providing an effective pathway for translating innovation and R&D into commercial value, while regulating the competitive market for established medicines, assisting the industry with the elimination of competition racing to the bottom and transformation towards innovation-driven development.

Reimbursement system diversified and expanded. In May 2026, the National Healthcare Security Administration issued the 2026 Medical Insurance Catalogue and the Adjustment Plan for the Commercial Health Insurance Innovative Drugs Catalogue, introducing for the first time a dedicated catalogue for innovative drugs under commercial health insurance. This catalogue prioritises the inclusion of innovative drugs that go beyond the scope of basic healthcare coverage, are not yet included in the basic catalogue but defined by a high degree of innovation, and offer significant clinical value and substantial patient benefits. This adjustment not only achieved a substantial expansion of the diversified reimbursement system but also further refined the multi-tiered pharmaceutical coverage system, broadened reimbursement pathways for innovative drugs, shortened the commercialisation timeline, and helped expand the market coverage and clinical application of innovative drugs.

Introduction of innovative drugs to the base level accelerated. In July 2026, the National Health Commission issued the "National Essential Medicines List (2026 Edition)", adding 116 new items and for the first time with the inclusion of innovative drugs within the selection scope. Considering current circumstances of the industry, the new list includes 16 innovative drugs with high clinical value and a broad patient population, suitable for use by healthcare institutions at all levels, thereby accelerating the delivery of the benefits of pharmaceutical innovation to the grassroots communities. At the institutional level, the new Essential Medicines List is seamlessly integrated with the Medical Insurance Catalogue. All newly added items have been included in medical insurance coverage. Future updates to the Medical Insurance Catalogue will be dynamically optimised and adjusted in line with the Essential Medicines List, with priority given to reclassifying eligible medicines into Categories A and B to continuously reduce the financial burden of medication costs on patients.

II. Industry Trends:

China's Innovative Drugs Rapidly Gaining Global Competitiveness

Supported by multiple policy empowerment, the competitiveness of China's innovative drugs industry has been enhanced and is profoundly reshaping the global landscape. With efficient R&D capabilities and significant cost advantages, Chinese pharmaceutical companies continue to deliver innovative outcomes with strong international competitiveness, establishing themselves as key targets for strategic partnerships and asset acquisitions by MNCs. In the first half of 2026, the total amount of out-licensing transactions for innovative drugs in China reached around US$110 billion, with 81 transactions in total, setting a new record high and was already 80% of the total transaction value for the year 2025. The transactions encompassed 10 therapeutic areas, including oncology, metabolism, immunology and neurology, fully demonstrating the growing global commercial value and industry influence of China's innovative drugs. The Group has seized industry opportunities and actively promoted the global expansion of Chinese innovation. In March 2026, the Group entered into an exclusive license agreement with Sanofi regarding Rovadicitinib, entitling the Group to a maximum payment of US$1.53 billion, as well as up to double-digit royalties based on the annual net sales. In July 2026, the Group entered into an exclusive license agreement with AstraZeneca regarding TQC3721, entitling the Group to a maximum payment of US$1.9 billion, as well as double-digit royalties based on the annual net sales.

Speeding up industry consolidation, and concentration of resources in leading companies

The Chinese pharmaceutical industry is undergoing accelerated consolidation with steadily increasing industry concentration. As centralised procurement policies continue to be refined, the industry is moving away from the early, simplistic "volume-for-price" model towards a high-quality, standardised development path characterised by "stabilising clinical practice, ensuring quality, preventing bid-rigging and combating internal competition". This places stricter demand on quality control, large-scale production and cost management capabilities, in order to drive out inefficient production quickly and promote a continued concentration of market share among leading companies with advantages in scale and integration. In the first half of 2026, a total of 52 M&A transactions were completed in the global biopharmaceutical industry, with resources flowing towards pharmaceutical companies possessing integrated capabilities in innovative R&D and commercialisation.

Leveraging its position as an industry leader, the Group has fostered the integration of global high-quality innovation resources. By pursuing a dual-track approach of strategic M&A and the introduction of external pipelines, it has continued to expand its differentiated innovation pipeline, refine its cutting-edge technology platforms and strengthen its competitive edge in core therapeutic areas. In terms of strategic acquisitions, in January 2026, the Group acquired Hygieia, a world-leading siRNA delivery technology platform, for RMB1.2 billion, making a strong entry into the trillion-level chronic disease management sector. In terms of product introductions, in May and July 2026, the Group introduced three blockbuster products, namely, bepirovirsen, Trelegy Ellipta® and Anoro Ellipta® from GlaxoSmithKline, effectively boosting the performance of its domestic commercialisation platform and further consolidating its leading position in the two core therapeutic areas of hepatology and respiratory medicine.

PERFORMANCE SUMMARY

For the six months ended 30 June 2026, the Group recorded revenue of approximately RMB19.44 billion, representing an increase of approximately 10.6% over the same period in last year; the sales revenue of innovative drugs and out-licensing was approximately RMB8.79 billion, representing an increase of approximately 44.3% over the same period in last year, and the proportion of total revenue rose to approximately 45.2%.

Core Therapeutic Areas	Approved Key Products
Oncology (Product revenue amounted to approximately RMB8.06 billion, accounting for approximately 41.4% of the total revenue)	Innovative drugs: Focus V® (Anlotinib Hydrochloride Capsules), Annike® (Penpulimab Injection), Yilishu® (Efbemalenograstim Alfa Injection), Andewei® (Benmelstobart Injection), Anboni® (Unecritinib Fumarate Capsules), Anluoqing® (Envonalkib Citrate Capsules), Anfangning® (Garsorasib Tablets), Anxu® (Rovadicitinib Tablets)*, Saitanxin® (Culmerciclib Capsules), Hernexeos® (Zongertinib Tablets) Biosimilars/Generic drugs: Anbeisi® (Bevacizumab Injection), Delituo® (Rituximab Injection), Saituo® (Trastuzumab for Injection), Paletan® (Pertuzumab Injection)
Liver/Cardiometabolic Diseases (Product revenue amounted to approximately RMB3.38 billion, accounting for approximately 17.4% of the total revenue)	Innovative drugs: Tianqing Ganmei® (Magnesium Isoglycyrrhizinate Injection) Biosimilars/Generic drugs: Runzhong® (Entecavir Dispersible Tablets)
Surgery/Analgesia (Product revenue amounted to approximately RMB3.21 billion, accounting for approximately 16.5% of the total revenue)	Innovative drugs: Zepolas®/Debaian® (Flurbiprofen Cataplasms), Zepolas® (Flurbiprofen Patch), Pu Yi Ke® (Peceleganan Spray), Symproic® (Naldemedine Tablets), Putanning® (Meloxicam Injection (II)), Debaining® (Lidocaine Cataplasms), Kailitong® (Limaprost Tablets) Biosimilars/Generic drugs: Deshuping® (Loxoprofen Sodium Cataplasms)

Core Therapeutic Areas	Approved Key Products
Respiratory/Autoimmune Diseases (Product revenue amounted to approximately RMB1.36 billion, accounting for approximately 7.0% of the total revenue)	Innovative drugs: Trelegy Ellipta® (Fluticasone Furoate inhalation powder), Anoro Ellipta® (Umebromide and Vilanterol Inhalation Powder) Biosimilars/Generic drugs: Tianqing Suchang® (Budesonide Suspension for Inhalation), Deruituo® (Tulobuterol Patches)

* In March 2026, the Group announced that it had granted Sanofi an exclusive license to develop, manufacture and commercialise Rovadicitinib globally, and was entitled to a maximum payment of US$1.53 billion, as well as up to double-digit royalties based on the annual net sales of Rovadicitinib.

Business Review

Since 2026, the Group has had a total of four National Class 1 or Class 2 innovative drugs approved for marketing by the NMPA, Anxu® (Rovadicitinib Tablet), Pu Yi Ke® (Peceleganan Spray), Symproic® (Naldemedine Tablets) and Zepolas® (Flurbiprofen Patch). Additionally, four new indications for three national category 1 innovative drugs were approved for marketing by the NMPA, namely: Saitanxin® (Culmerciclib Capsules) in combination with fulvestrant for the first-line treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer, Hernexeos® (Zongertinib Tablets) as monotherapy for the first-line treatment of unresectable locally advanced or metastatic non-small cell lung cancer harbouring HER2 (ERBB2) tyrosine kinase domain activating mutations, and FOCUS V® (Anlotinib Hydrochloride Capsules) in combination with Andewei® (Benmelstobart Injection) for the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer and for the treatment of advanced or unresectable alveolar soft part sarcoma.

Regarding out-licensing collaboration, in March 2026, the Group has granted Sanofi an exclusive license to develop, manufacture and commercialise Rovadicitinib globally, entitling the Group to an initial payment of US$135 million and, together with potential payments regarding development, regulatory, and sales millstones, an aggregate payment up to US$1.53 billion, as well as up to double-digit royalties based on the annual net sales of Rovadicitinib. In July 2026, the Group granted AstraZeneca an exclusive licence to develop, manufacture and commercialise TQC3721 outside China, as well as a global exclusive licence for a specific development programme for TQC3721, entitling the Group to a maximum payment of US$200 million, together with potential payments regarding development, regulatory, and sales millstones, an aggregate payment up to US$1.9 billion, as well as double-digit royalties based on the annual net sales.

For the six months ended 30 June 2026, the Group's revenue from innovative drugs and out-licensing collaboration reached RMB8.79 billion, representing an increase of approximately 44.3% over the same period in last year and accounting for 45.2% of the total revenue.

R&D

The Group has consistently regarded Innovative R&D as its core driving force and the cornerstone of sustainable development, continuously increasing R&D investment, striving to improve R&D capabilities and efficiency. At present, the Group has established multiple R&D centers in Shanghai, Nanjing, Beijing, Guangzhou and other cities, and has successfully built diversified innovative technology platforms covering small molecules, protein degraders, siRNA, monoclonal antibodies/ bispecific antibodies/multi-antibodies, ADC, inhalable formulations, transdermal patches and other fields. For the six months ended 30 June 2026, total investment in R&D of the Group amounted to approximately RMB3,290.98 million, representing approximately 16.9% of the Group's revenue, of which approximately 93.6% was recognised in the statement of profit or loss.

ONCOLOGY

– Focus V® (Anlotinib Hydrochloride Capsules) is a novel small molecule multi-target tyrosine kinase inhibitor. It has been approved for twelve indications, including first-line squamous non-small cell lung cancer, first-line small cell lung cancer, third-line non-small cell lung cancer, third-line small cell lung cancer, first-line hepatocellular carcinoma, first-line renal cell carcinoma; first-line soft tissue sarcoma, second-line or later endometrial cancer, soft tissue sarcoma, medullary thyroid carcinoma, differentiated thyroid cancer and alveolar soft part sarcoma; a number of new indications, such as first-line non-squamous non-small cell lung cancer and first-line pancreatic cancer, are currently in Phase III clinical studies, with plans to gradually submit marketing applications within the next two years. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the Group presented data from a Phase III clinical trial evaluating anlotinib in combination with benmelstobart as first-line treatment for non-squamous non-small cell lung cancer (NSCLC). This is the second head-to-head Phase III study in which benmelstobart in combination with anlotinib has demonstrated superior efficacy over tislelizumab in combination with standard chemotherapy, following the positive result previously observed in squamous NSCLC. Notably, this is the first Phase III trial globally to report a positive outcome in first-line non-squamous NSCLC versus an immune checkpoint inhibitor (ICI) plus chemotherapy.

– Andewei® (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody. It has been approved for six indications, including first-line squamous non-small cell lung cancer, maintenance therapy after chemoradiotherapy for non-small cell lung cancer, first-line small cell lung cancer, second-line or later endometrial cancer, first-line renal cell carcinoma, and alveolar soft part sarcoma. In addition, Phase III clinical trials are currently underway for several other new indications, including maintenance therapy for limited-stage small cell lung cancer and first-line treatment of PD-L1-positive non-small cell lung cancer. The "immunotherapy + anti-angiogenesis" treatment mode of benmelstobart in combination with anlotinib has a synergistic effect in tumor treatment. This combination regimen has demonstrated breakthrough therapeutic potential in various malignant tumors such as first-line non-small cell lung cancer and first-line small cell lung cancer, and is expected to bring better and more accessible treatment options to patients.

– Saitanxin® (Culmerciclib Capsules) is a novel CDK2/4/6 inhibitor that has currently been approved for two indications, in combination with fulvestrant for the treatment of: first-line treatment of hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer, and HR+/HER2- locally advanced or metastatic breast cancer in patients who have experienced disease progression following prior endocrine therapy. In addition, the Group is actively advancing the phase III clinical study of culmerciclib for adjuvant treatment of HR+/HER2- breast cancer, with a marketing authorisation application expected to be submitted within the next two years. The research results indicate that compared with abemaciclib, culmerciclib further enhances the inhibition of CDK2 and CDK4, which may effectively overcome the resistance issues associated with existing CDK4/6 inhibitors. Relying on its excellent efficacy and safety profile and its coverage across first-line, second-line, and adjuvant therapy for breast cancer, the Group is confident that culmerciclib will become another blockbuster product in the oncology field.

– Hernexeos® (Zongertinib Tablets) is the world's first and currently only approved oral HER2 tyrosine kinase inhibitor; it has currently been approved for two indications: first-line treatment for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer harbouring HER2 (ERBB2)-activating mutations, and for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer harbouring HER2 (ERBB2)-activating mutations who have previously received at least one prior systemic therapy. In 2024, the Group announced a strategic collaboration with Boehringer Ingelheim to leverage the complementary strengths of both companies to provide cancer patients in China with more and better treatment options. Both parties will collaborate on various innovative oncology products from Boehringer Ingelheim that are in late-stage clinical development. Zongertinib is one of the products under the strategic collaboration between Boehringer Ingelheim and the Group in mainland China.

– Anxu® (Rovadicitinib Tablet) is the first JAK/ROCK dual inhibitor approved for marketing in the world. It was approved by the NMPA in February 2026 for the first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), postpolycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF). Rovadicitinib targets both JAK1/2 and ROCK1/2 simultaneously, exerting dual anti-inflammatory and anti-fibrotic effects. Currently, a Phase III clinical trial of rovadicitinib for the treatment of chronic graft-versus-host disease (cGVHD) has been initiated in China, and a Phase II clinical trial has been approved in the US. In March 2026, the Group announced the grant of an exclusive license to Sanofi for the global development, manufacturing, and commercialisation of rovadicitinib, with the Group eligible to receive payments of up to US$1.53 billion, as well as up to double digit royalties based on the annual net sales of rovadicitinib.

– Regarding the R&D pipeline, as at the end of the reporting period, the Group had a total of 39 national category 1 innovative oncology drug candidates in the clinical development stage or beyond. Of these, 5 were at the marketing application stage, 12 were in Phase III clinical trials, 7 were in Phase II clinical trials, and 15 were in Phase I clinical trials.

– M701 (CD3/EpCAM bispecific antibody) is a CD3/EpCAM bispecific antibody with potential as an FIC therapy in China, an application for marketing of which was submitted to the CDE in May 2026 for the treatment of malignant ascites (MA) caused by advanced epithelial malignancies. Meanwhile, a Phase II clinical trial of M701 for malignant pleural effusion (MPE) caused by non-small cell lung cancer has completed patient enrollment. M701 targets both the tumor cell target EpCAM and the immune T cell activation target CD3, and bridges tumor cells and immune T cells through dual-target binding, thereby activating T cells to kill tumor cells. Malignant pleural effusion and ascites are common complications for cancer patients at the middle or advanced stages; approximately 50 per cent of patients with advanced malignant tumours develop these effusions as their disease progresses, directly affecting their quality of life and survival. However, there is currently a lack of effective standard treatment options in clinical practice, and puncture drainage combined with local pleural or peritoneal infusion of drugs is still the primary treatment. Compared with the current primary clinical treatments, M701 has better safety and efficacy, and is expected to become the first standard of care for malignant pleural effusion and ascites in China.

– LM-302 (tecotabart vedotin, Claudin 18.2 ADC) is an ADC targeting Claudin 18.2. An application for marketing was submitted to the CDE in June 2026 for its use as a monotherapy in patients with CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma who have received at least two prior systemic therapies. Moreover, LM-302 in combination with PD-1 monoclonal antibody is currently undergoing a Phase III registration clinical trial in China for the treatment of first-line CLDN18.2-positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, with the first patient having been enrolled. This marks the world's first Phase III clinical trial of a CLDN18.2 ADC using a chemotherapy-free regimen for the first-line treatment of gastric cancer. Both of the aforementioned indications have been included in the CDE's Priority Review and approval programme. Additionally, LM-302 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and has been granted three Orphan Drug Designations (ODD), covering three major gastrointestinal tumors with high unmet clinical needs: gastric, pancreatic, and biliary tract cancers. Clinical data suggest that LM-302 has demonstrated clear anti-tumor activity in patients with gastric, pancreatic, and biliary tract cancers, and is also effective in patients with low Claudin 18.2 expression and low PD-L1 expression, demonstrating broader applicability and a favorable therapeutic window over existing therapies, achieving a better balance between efficacy and safety.

– LM-108 (cafelkibart，CCR8 monoclonal antibody) is an antibody-dependent cellular cytotoxicity (ADCC)- enhanced CCR8 humanized monoclonal antibody with global FIC potential. It is currently undergoing two pivotal clinical trials in China, both in combination with a PD-1 monoclonal antibody: 1) for the second-line treatment of CCR8-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma, and enrollment of the first participant was completed in May 2026; 2) for the treatment of unresectable or metastatic MSI-H/dMMR advanced malignant solid tumors that have failed previous anti-PD-1/PD-L1 therapy. The two abovementioned indications have been granted Breakthrough Therapy Designation. Early exploratory clinical studies

have shown that LM-108 demonstrates favorable safety and preliminary anti-tumor activity in the treatment of various solid tumors such as gastric cancer, pancreatic cancer, lung cancer, and breast cancer, especially in PD-1/PD-L1 resistant or refractory patients. With its ability to precisely target immunosuppressive cells in the tumor microenvironment, LM-108 has the potential to become a key pillar of next-generation cancer immunotherapy, providing more breakthrough treatment options for patients with advanced solid tumors.

– TQB2102 (HER2 bispecific ADC) is a bispecific ADC that simultaneously targets the HER2 ECD II/IV domains. It is currently undergoing several Phase III clinical trials in China, including in chemotherapy-naïve advanced HER2-low breast cancer, advanced HER2-positive breast cancer after prior anti-HER2 therapy, neoadjuvant HER2-positive breast cancer; first-line advanced HER2-positive breast cancer, later-line advanced HER2-positive biliary tract cancer, and advanced HER2-positive colorectal cancer that has failed treatment with oxaliplatin, irinotecan and fluorouracil-based regimens. TQB2102 has had three indications included in the CDE's Breakthrough Therapy Programme, namely: 1) neoadjuvant treatment for HER2-positive early-stage or locally advanced HER2- positive breast cancer; 2) HER2 IHC 3+ advanced colorectal cancer that has previously failed treatment with oxaliplatin, irinotecan and fluorouracil; 3) unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer in patients who have not previously received chemotherapy. At the 2025 ASCO Annual Meeting, the Group announced the results of three early-stage studies of TQB2102, showing that TQB2102 demonstrated promising anti-tumor activity across multiple advanced solid tumors, with a favorable safety profile and an incidence of interstitial lung disease (ILD) significantly lower than that of similar drugs, achieving a well-balanced profile of efficacy and safety.

– TQB2868 (PD-1/TGF-β bifunctional fusion protein) is the most advanced PD-1/TGF-β bifunctional fusion protein globally. It is currently undergoing Phase III clinical trials in China for use in combination with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. TQB2868 can block the PD-1/PD-L1 pathway and neutralize TGF-β in the tumor microenvironment. It has the dual effects of immune checkpoint suppression and tumor microenvironment remodeling. At the 2025 ASCO Annual Meeting, the Group presented data from the Phase II clinical study of TQB2868 combined with anlotinib and chemotherapy as a first-line treatment for metastatic pancreatic ductal adenocarcinoma: the objective response rate (ORR) was 63.9%, and the disease control rate (DCR) reached 100%; median progression free survival (PFS) had not yet been reached, with a 6-month PFS rate of 86%; median overall survival (OS) had not yet been reached and is anticipated to exceed one year.

– TQB3019 (BTK OAPD) is an oral protein degrader targeting BTK developed based on the OAPD® (Orally Available Protein Degrader) technology platform of the Group. It is currently conducting phase I clinical trials in China for advanced malignancies. Compared with conventional BTK inhibitors, protein degraders demonstrate more prominent therapeutic potential in overcoming BTK resistance. At present, no protein degraders targeting BTK have been approved for marketing worldwide. TQB3019 exhibits broad activity against BTK wild-type, C481 mutant and many other resistant variants, while also demonstrating favorable oral bioavailability and brain tissue

penetration. Phase I clinical studies have shown encouraging efficacy even in the initial dose cohort: 4 of the 5 enrolled patients with mantle cell lymphoma (MCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) achieved partial response, while pharmacodynamic analysis showed near-complete BTK degradation.

Liver/Cardiometabolic Diseases

– Tianqing Ganmei® (Magnesium Isoglycyrrhizinate Injection) is the fourth generation of glycyrrhizic acid preparation that has been approved for three indications: chronic viral hepatitis, acute drug-induced liver injury, and improvement of liver dysfunction. This medicine is the world's first 99.9% purified alpha-glycyrrhizic acid. It has the advantages of strong liver targeting, excellent anti-inflammatory effects, and good safety. It has been recommended by the "Chinese Guideline for Diagnosis and Management of Drug-Induced Liver Injury (2023 Edition)", the "Guideline for the Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)", "Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury in Cancer Patients (2025 Edition)" and other authoritative guidelines. It also has many studies presented at the annual meeting of the Asia Pacific Association for the Study of the Liver (APASL), the European Association for the Study of the Liver (EASL), and other internationally renowned academic conferences. The Group made efforts to strengthen the academic promotion, expanding doctor coverage and gaining recognition from experts through academic conferences at all levels, while vigorously exploring new patients to expand into new markets, and actively promoting retrospective research to provide more academic evidence for its clinical use.

– Regarding the R&D pipeline, as at the end of the reporting period, the Group had a total of 12 national category 1 innovative drug candidates in the fields of liver/cardiometabolic diseases in the clinical development stage or beyond. Of these, 1 was at the marketing application stage, 2 were in Phase III clinical trials, 3 were in Phase II clinical trials, and 6 were in Phase I clinical trials.

– Bepirovirsen (ASO) is a first-in-class triple action antisense oligonucleotide (ASO). A marketing application for its use in the treatment of chronic hepatitis B (CHB) in adults was submitted to the CDE in March 2026, and has been granted Priority Review status. In May 2026, the results of two Phase III clinical trials of bepirovirsen – B-Well 1 and B-Well 2 – were published simultaneously in the "New England Journal of Medicine" and presented at the 2026 EASL Annual Meeting. Pooled data from the two trials showed that six months' treatment with bepirovirsen achieved a statistically and clinically significant functional cure rate of 19% in the overall study population (adults with hepatitis B surface antigen (HBsAg) levels ≤3,000 IU/ml), thereby meeting the primary endpoint. A key secondary endpoint showed that the functional cure rate reached 26% among participants with HBsAg levels ≤1,000 IU/ml, a group representing approximately 45% of diagnosed cases of chronic hepatitis B worldwide. Currently, standard treatment for chronic hepatitis B in adults typically requires lifelong medication, with a functional cure rate of less than 1 per cent. Bepirovirsen is expected to receive a regulatory decision from the NMPA in the first half of 2027 and is poised to become the world's first approved drug for the functional cure of hepatitis B. In May 2026,

the Group's subsidiary, CT Tianqing, entered into an exclusive strategic partnership with GSK. According to the arrangement, CT Tianqing will be responsible for the importation, distribution, hospital access, and promotional and non-promotional activities for bepirovirsen in mainland China. Revenue generated from the sales of bepirovirsen in China is expected to be recognised by CT Tianqing as operating revenue.

– Lanifibranor (pan-PPAR agonist) is an orally available small molecule drug that is currently undergoing Phase III clinical trials worldwide for the treatment of metabolic dysfunction associated steatohepatitis (MASH), and enrollment of patients in the global main cohort has been completed. It is a potential FIC oral drug for MASH in China. In a randomized, double-blind, placebo-controlled Phase IIb study in patients with MASH stage F1 to F3, Lanifibranor demonstrated excellent efficacy and good safety. The study met the primary endpoint and key secondary endpoint, and the results have been published in the authoritative international journal "New England Journal of Medicine" (NEJM). Lanifibranor regulates antifibrosis and anti-inflammatory pathways in vivo by activating three subtypes, PPAR α, PPAR β/δ and PPAR γ. Compared with single/dual subtype agonists, Lanifibranor targets all three subtypes, and its moderate and balanced pan-PPAR binding properties make the drug well tolerated. In July 2023, Lanifibranor was granted Breakthrough Therapy Designation by the CDE.

– Kylo-11 (Lp(a) siRNA) is the first ultra-long-acting Lp(a) siRNA in the world designed for once-yearly dosing, and is currently undergoing Phase II clinical trials in China and the United States for the treatment of Hyperlipoproteinemia(a). Enrollment of all trial participants in China has now been completed. Kylo-11 was developed using the MVIP (Multi-valent Introduction Platform) delivery platform, which was independently established by Hygieia, and has the potential to be best-in-class (BIC). MVIP is the first siRNA delivery platform in China to have been granted a global patent. Its world-first dual-conjugated siRNA delivery technology for liver diseases effectively prevents exonucleases from degrading the terminal fragments of the antisense strand and reduces the degradation of the antisense strand in plasma, thereby achieving highly efficient delivery and long-term stability. The Phase I interim clinical data of Kylo-11 was presented in an oral report at the 2025 American Heart Association (AHA) Annual Meeting. Data showed that in healthy subjects with elevated Lp(a), a single low-dose administration can achieve a maximum median Lp(a) reduction of more than 90%, while medium and high doses demonstrated potential to sustain significant efficacy for more than one year. Compared with similar investigational drugs at home and abroad, Kylo-11 shows BIC potential in terms of efficacy and durability, and has the advantages of low dosage and good safety. Currently, no drug specifically indicated for lowering Lp(a) has been approved for marketing worldwide, and there is a significant unmet clinical need in this area.

– Kylo-12 (APOC3 siRNA) is an APOC3 siRNA with global BIC potential, which is expected to be dosed semi-annually (or at longer intervals). It is currently in a Phase I clinical trial in China, planning to initiate Phase II clinical trial in 2026 for the treatment of hypertriglyceridemia (HTG) and familial chylomicronemia syndrome (FCS). For patients who do not respond adequately to conventional lipid-lowering treatments, APOC3 siRNA therapy aims to provide a highly effective and convenient new solution, with the potential to address current treatment gaps and fill unmet needs in the market.

– Kylo-0603 (THR-β agonist) is the world's first THR-β small molecule agonist that achieves specific liver targeting by conjugating GalNAc, and has completed a Phase I clinical trial in China for the treatment of MASH. Kylo-0603 has both GalNAc structure and thyroid hormone T3- like structure, enabling efficient liver targeted delivery, high affinity and selectivity for THR-β, and can precisely deliver thyroxine-like compounds to the liver, reducing extrahepatic side effects. With the dual targeting advantages of liver and THR-β receptors, Kylo-0603 is expected to achieve better efficacy and safety at lower doses, providing a new oral treatment option for metabolic diseases such as MASH and weight loss. At the 2026 European Association for the Study of the Liver (EASL) Annual Meeting, the Group announced the Phase I clinical data for Kylo-0603, which demonstrated good safety and lipid-lowering effects. Thanks to its dual-targeting mechanism of action on the liver and THR-β receptors, it is expected to achieve superior efficacy and safety at lower doses, offering a novel oral treatment option for metabolic conditions such as MASH and weight loss.

Respiratory/Autoimmune Diseases

– Trelegy Ellipta® (FF/UMEC/VI) is a combination of three molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains fluticasone furoate (FF), an inhaled corticosteroid (ICS), umeclidinium (UMEC), a long-acting muscarinic antagonist (LAMA), and vilanterol (VI), a long-acting beta2-adrenergic agonist (LABA). FF/UMEC/VI was first approved in China in 2019 for maintenance treatment of chronic obstructive pulmonary disease (COPD), and in 2026, it received approval for an additional indication for maintenance treatment of asthma, and became the first and the only single-inhaler triple therapy (SITT) in China indicated for maintenance treatment of both asthma and COPD. Anoro Ellipta® (UMEC/VI) is a combination of two molecules in a single inhaler that only needs to be taken in a single inhalation, once a day. It contains two active ingredients: LAMA UMEC and LABA VI. UMEC/VI was approved in China in 2018 for long-term maintenance treatment of COPD. In 2025, the combined global sales of these two medicines exceeded £3.5 billion. In July 2026, the Group's subsidiary, CT Tianqing, further deepened its strategic collaboration with GSK, expanding the scope of their partnership from liver diseases to respiratory diseases. The Group has acquired the commercialisation rights for Trelegy Ellipta® and Anoro Ellipta® in mainland China; all sales revenue generated by these products will be recognised as operating revenue of CT Tianqing.

– Regarding the R&D pipeline, as at the end of the reporting period, the Group had a total of 10 national category 1 innovative drug candidates in the field of respiratory/autoimmune diseases in the clinical development stage or beyond. Of these, 6 were in Phase III clinical trials, 2 were in Phase II clinical trials, and 2 were in Phase I clinical trials.

– TQC3721 (PDE3/4 inhibitor) is an inhaled PDE3/4 inhibitor with global BIC potential. TQC3721 is being developed across nebulized and dry powder inhaler formulations, supporting use across different patient segments, disease severities and commercial settings. In COPD, TQC3721 in a nebulized formulation has generated phase IIb data that demonstrate a potential best-in-class profile study. The nebulized formulation is currently being evaluated in a Phase III clinical trial

in China, while the dry powder inhaler formulation is also being advanced in a Phase II clinical trial. TQC3721 has the potential to become the first domestically developed inhaled dual PDE3/4 inhibitor approved in China. Through balanced inhibition of both PDE3 and PDE4, TQC3721 is designed to deliver synergistic bronchodilatory and anti-inflammatory effects, with the potential to improve lung function, reduce exacerbations and address broader disease burden in patients with chronic respiratory diseases. In July 2026, the Group granted AstraZeneca an exclusive license to develop, manufacture and commercialise TQC3721 outside China, and exclusive global rights for certain future development programmes. The Group is eligible to receive an upfront payment of US$200 million, with additional development, regulatory and sales milestones totalling up to USD$1.9 billion, as well as tiered royalties ranging up to double-digit percentages based on the annual net sales of TQC3721 products.

– TDI01 (ROCK2 inhibitor) is the first domestically developed ROCK2 inhibitor in China and is currently conducting phase III clinical trials in China for idiopathic pulmonary fibrosis (IPF). TDI01 can effectively inhibit pro-inflammatory Th17 cells, promote regulatory T cells, and restore immune homeostasis. At the same time, it inhibits the ROCK2 signaling pathway with high selectivity, blocks the differentiation of fibroblasts into myofibroblasts, and induces apoptosis of existing myofibroblasts, achieving the dual effects of immune modulation and fibrosis reversal, and has good therapeutic potential in the fields of pulmonary fibrosis and liver fibrosis.

– TQH3906 (TYK2 inhibitor) is a TYK2 allosteric inhibitor, currently undergoing Phase III clinical trials in China for moderate to severe plaque psoriasis. In addition, TQH3906 (TYK2 inhibitor) is currently undergoing Phase II clinical trials in China for inflammatory bowel disease (IBD) and psoriatic arthritis (PsA). TQH3906 targets the pseudokinase domain (JH2) of TYK2/JAK1, and significantly enhances selectivity for JAK2, JAK3, and other kinases, offering higher selectivity and a potentially better safety profile compared to conventional JAK inhibitors that target the kinase domain (JH1). In the Phase II clinical trial of TQH3906 in plaque psoriasis, all dose groups demonstrated favorable safety and tolerability and met the primary endpoint. Detailed data will be presented at a future international academic conference.

– TQC2731 (TSLP monoclonal antibody) is a humanized monoclonal antibody targeting TSLP, currently undergoing Phase III clinical trials in China for indications including severe asthma and chronic rhinosinusitis with nasal polyps. It is the first domestically developed TSLP monoclonal antibody to enter Phase III clinical trials. Studies have shown that TSLP monoclonal antibody is not only effective in the treatment of eosinophilic asthma, but also shows significant efficacy in people with low eosinophilic phenotypes, so it can cover a wider range of patients with severe asthma. In addition to asthma, TSLP is closely associated with the pathogenesis of various autoimmune diseases, chronic inflammatory diseases and allergic diseases.

SURGERY/ANALGESIA

– Zepolas®/Debaian® (Flurbiprofen Cataplasms) is the first domestically produced cataplasm approved for marketing in China, ranking first in the market share of topical analgesia for many years. It is recommended by many guidelines, including the "Expert Consensus on Diagnosis and Treatment of Chronic Musculoskeletal Pain" and "Chinese Guidelines for the Treatment of Chronic Pain Disorders with Non-Opioid Analgesics". The Group focuses on the development of high-potential regions, strengthening its retail channel network, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. In August 2026, the Group's second-generation flurbiprofen patch (Zepolas®) has received approval for marketing by the NMPA and has been granted a 4-year data protection period. With formulation enhancements, the second-generation product can significantly improve the transdermal absorption of the drug and enhance the adhesiveness of the plaster, thereby improving patient compliance.

– Putanning® (Meloxicam Injection (II)) is China's first once-daily long-acting nonsteroidal anti-inflammatory drug (NSAID) injection for postoperative pain management in adults. Two Phase III clinical studies demonstrated that Putanning maintains significant analgesic effects during the late stages of the drug effect (18- 24 hours) and can effectively alleviate pain between doses, especially nighttime pain during postoperative hospitalization. Compared with other NSAIDs, Putanning achieves a greater reduction in morphine consumption. In addition, Putanning can be used safely in special populations, such as patients with mild renal impairment and the elderly, with excellent safety.

– De Bai Ning® (Lidocaine Cataplasms) was approved for marketing in 2018 for the relief of postherpetic neuralgia (PHN), filling a gap in the domestic market for topical treatments for PHN. In 2025, De Bai Ning® was approved for a new indication, diabetic peripheral neuropathic pain (DPNP), becoming the world's first and currently only topical analgesic patch approved for this indication. The pathogenesis of DPNP is complex; existing oral medications are limited by prominent adverse reactions such as dizziness and drowsiness, as well as a high risk of opioid dependence, and treatment options are limited. De Bai Ning® can be used as monotherapy or in combination with oral medications. Studies have shown that in patients for whom oral monotherapy alone is insufficient, the pain relief rate can be increased to 78.2 per cent when combined with De Bai Ning®, with some patients being able to reduce or discontinue their oral medication. It is recommended by authoritative international guidelines as a supplementary or alternative treatment to first- or second-line oral medications.

– Regarding the R&D pipeline, as at the end of the reporting period, the Group had a total of 4 national category 1 or 2 innovative surgery/analgesia drug candidates in the clinical development stage or beyond. Of these, 1 was at the marketing application stage, 2 were in Phase II clinical trials, and 1 was in Phase I clinical trial.

– Pu Yi Ke® (Peceleganan Spray) has received approval for marketing by NMPA in June 2026 for the treatment of wound infections secondary to first-degree or superficial second-degree burns and scalds caused by Staphylococcus epidermidis, Staphylococcus haemolyticus and Acinetobacter baumannii. Peceleganan is the first-ever non-antibiotic antimicrobial agent of a novel design. Based on the theory of the "Membrane Discrimination Mechanism", it exerts bactericidal activity by disrupting the barrier function of bacterial biofilm systems. As a broad-spectrum antimicrobial peptide, its unique bactericidal mechanism exhibits strong bactericidal activity against a broad spectrum of drug-resistant pathogens, including the "superbug" MRSA and multidrug-resistant Acinetobacter baumannii strains harbouring the NDM-1 gene. Peceleganan is the first Ganan-class anti-infective drug in China to be named by the World Health Organisation (WHO).

– TRD205 (AT2R antagonist) is a non-opioid, highly selective antagonist targeting AT2R with global FIC potential. It is currently in Phase II clinical trials in China and has obtained IND approval from the U.S. FDA, with intended indications including chronic post-surgical neuropathic pain (CPSNP) and acute postoperative pain. In July 2026, TRD205 was designated for the Breakthrough Therapy Programme by the CDE, primarily based on a multi-center, randomized, double-blind, placebo-controlled, parallel-group and dose-exploratory Phase II clinical trial designed to evaluate its efficacy and safety in the treatment of chronic post-operative neuropathic pain. TRD205 exerts a multi-modal analgesia by highly selectively antagonising the peripheral AT2R receptors: on the one hand, TRD205 inhibits the migration of macrophages – which play a key role in pain – to the site of injury, reducing the expression of neurotransmitters, reactive oxygen species and inflammatory factors, thereby effectively reducing peripheral sensitization; on the other hand, multiple preclinical data indicate that TRD205 is capable of inhibiting the expression of pain-related ion channels, such as Nav1.8 and TRPV1, in the dorsal root ganglion (DRG), thereby suppressing neural excitation transmission. As it acts solely at the peripheral level, TRD205 is expected to avoid the adverse reactions – such as drowsiness and dizziness – associated with centrally acting drugs, thereby offering a solution to the challenge faced by patients with chronic pain who are unable to tolerate long-term medication.

– TRD208 (non-opioid multi-target multi-modal analgesic) is a first-in-class, non-opioid, multitarget, multi-modal analgesic. It is currently in Phase I clinical trials in China for postoperative analgesia in adults and has obtained IND approval from the U.S. FDA. With its unique multitarget mechanism of action, TRD208 is capable of blocking multiple pain-related transmission pathways in the central nervous system, including NaV1.7, NaV1.8 and others, while also delivering peripheral anti-inflammatory and analgesic effects similar to NSAIDs and inhibiting central sensitization. This approach may help reduce the risk of neuropathic pain arising from acute pain. As demonstrated by the pre-clinical data, TRD208 demonstrates rapid onset, potent analgesic effects, and prolonged duration of action in the model of postoperative pain. As a non-opioid drug with multitarget synergistic effects, TRD208 is expected to achieve multi-modal analgesic effects with a single agent, which may potentially replace current mainstream combination therapies. This will simplify treatment regimens, improve patient compliance while avoiding the risk of opioid dependence.

Financial Review

During the period, the Group recorded revenue of approximately RMB19,444.36 million, an increase of approximately 10.6% over the same period last year. Profit attributable to owners of the parent as reported was approximately RMB3,434.60 million, an increase of approximately 1.4% over the same period last year. Basic earnings per share based on profit attributable to owners of the parent as reported were approximately RMB19.10 cents, an increase of approximately 1.5% over the same period last year. The year-on-year increase in profit attributable to owners of the parent as reported was mainly driven by a notable growth in revenue and a decrease in dividend income and fair value gain on investments during the period. Excluding the amortisation of newly identified intangible assets, the share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests), fair value changes and the impairment of one-off adjustments of certain assets and liabilities (net of related tax and non-controlling interests), fair value (gains)/losses of current equity investments, net (net of related tax and non-controlling interests), share-based payment (net of related tax and non-controlling interests), effective interest expenses and exchange loss of the convertible bond debt component, etc., underlying profit attributable to owners of the parent (non-HKFRS measure) was approximately RMB3,339.32 million, an increase of approximately 8.1% over the same period last year. Excluding dividend income from Sinovac LS, underlying profit significantly rose by RMB1.6 billion, representing an increase of 92.3% year-on-year.

The Group's liquidity remains strong. As at the end of the current period, the Group's fund reserve was approximately RMB34,583.64 million (31 December 2025: approximately RMB32,990.24 million), net cash (including wealth management products) was approximately RMB17,412.19 million (31 December 2025: approximately RMB16,920.23 million).

Continuing operations

The major therapeutic areas of the Group include oncology medicines, liver/cardiometabolic diseases medicines, respiratory/autoimmune diseases medicines and surgery/analgesia medicines. These are categorized into innovative drugs, out-licensing, biosimilars and generics drugs. Among them, innovative drugs and out-licensing, are the primary driver of the Group's performance growth.

Innovative drugs and out-licensing

For the six months ended 30 June 2026, the sales of innovative drugs and out-licensing amounted to approximately RMB8,789.40 million, representing approximately 45.2% of the Group's revenue, an increase of approximately 44.3% over the same period last year.

NON-HKFRS MEASURE

For the purpose of assessing the performance of the Group, the Company has also presented the underlying profit attributable to owners of the parent as an additional financial measure, which is not required by, or presented in accordance with the Hong Kong Financial Reporting Standards ("HKFRS"). The Group believes that this non-HKFRS financial measure better reflects the underlying operational performance of the Group by eliminating certain non-operating, non-cash (i.e. non-recurring gains and losses that are not related to continuing operations, such as discontinued operations, significant asset impairment, equity settled share-based payments, etc.) and non-recurring (i.e. gains and losses from non-core businesses (businesses other than the Group's research and development, production and commercialization of innovative drugs, biosimilars and generic drugs and out-licensing), including investments in associates and joint ventures, and fluctuations in the fair value of financial assets (financial investments), etc.) items which the Group does not consider indicative of the Group's fundamental operating performance. However, the presentation of this non-HKFRS financial measure is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with HKFRS. Underlying profit attributable to owners of the parent for the period increased by approximately 8.1% over the same period last year.

Effective 1 January 2025 we refined the definition of underlying profit attributable to owners of the parent as follows, and have updated prior period comparative figures to reflect the change, which is excluding intangible asset amortization on acquired intangibles from merger and acquisition. Additional detail on this adjustment is provided below.

Underlying profit attributable to owners of the parent is presented excluding the impact of the following item from profit attributable to owners of the parent as reported:

Intangible asset amortization – the amortization expense associated with finite life intangible assets arising from acquisitions or business combinations.

Additional information is provided below to reconcile the profit attributable to owners of the parent as reported and the underlying profit attributable to owners of the parent:

	For the six months ended 30 June		
	2026	2025	Change
	RMB'000	*RMB'000*	*%*
	(Unaudited)	(Unaudited)	
Profit attributable to owners of the parent as reported	**3,434,598**	3,388,591	+1.4%
Adjusted for:			
Amortisation of newly identified intangible assets	**1,235**	1,188	
Share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests)	**25,092**	3,500	
Fair value changes and the impairment of one-off adjustments of certain assets and liabilities (net of related tax and non-controlling interests)	**(61,878)**	(332,902)	
Fair value (gains)/losses of current equity investments, net (net of related tax and non-controlling interests)	**(127,803)**	4,849	
Share-based payment (net of related tax and non-controlling interests)	**68,074**	23,501	
Convertible bond debt component of:			
– Interest expenses	**–**	46	
– Exchange loss	**–**	65	
Underlying profit attributable to owners of the parent	**3,339,318**	3,088,838	+8.1%
Basic earnings per share			
Underlying profit attributable to owners of the parent used in the basic earnings per share calculation	**3,339,318**	3,088,838	+8.1%
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation (Shares)	**17,983,011,615**	18,003,635,574	
Basic earnings per share, based on underlying profit attributable to owners of the parent (RMB cents)	**18.57**	17.16	+8.2%

The Company provides the reconciliation of the following Non-HKFRS financial metrics adjusting items to further illustrate the relationship between these adjusting items and the HKFRS financial data. These additional figures provide our shareholders and investors with useful supplementary information about our ongoing operating performance of the Group's core business and facilitates the analysis and comparison of financial measures between periods.

The use of these non-HKFRS measures may have certain limitations as a tool for analysis and comparison. Shareholders and investors are advised not to consider these non-HKFRS measures in isolation from, or as a substitute for analysis of, the Group's financial performance as reported under HKFRS. Also, please note that these non-HKFRS measures may be defined differently from similar terms used by other companies.

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
1. Share of profits and losses of associates and joint ventures (net of related tax and non-controlling interests)		
Share of loss of associates and joint ventures	**(27,546)**	(4,823)
Related tax	**419**	(1,955)
Non-controlling interests	**2,035**	3,278
Adjusted amount	**(25,092)**	(3,500)
2. Share-based payments (net of related tax and non-controlling interests)		
Equity settled share-based payments	**(84,931)**	(58,628)
Related tax	**3,104**	18,939
Non-controlling interests	**13,753**	16,188
Adjusted amount	**(68,074)**	(23,501)
3. Fair value changes and the impairment of one-off adjustments of certain assets and liabilities (net of related tax and non-controlling interests)		
Fair value changes of financial assets at fair value through profit or loss (non-current), net	**36,012**	541,479
Impairment loss on other receivables	**–**	(211,273)
Gain on deemed partial disposal of an associate	**1,124**	352
Gain from changes in the fair value of contingent consideration	**25,840**	–
Related tax	**(1,098)**	2,344
Adjusted amount	**61,878**	332,902

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
4. Fair value gains/(losses) of current equity investments, net (net of related tax and non-controlling interests)		
Fair value changes of equity investments designated at fair value through profit or loss, net	**150,687**	(16,112)
Related tax	**(7,678)**	3,448
Non-controlling interests	**(15,206)**	7,815
Adjusted amount	**127,803**	(4,849)

Financial assets at fair value through profit or loss represent financial investments in listed companies, with valuation changes reflecting market factors rather than the sales and R&D of the Group's pharmaceutical products.

5. Amortisation of newly identified intangible assets (net of related tax and non-controlling interests)		
Amortisation of newly identified intangible assets	**3,553**	3,553
Related tax	**(533)**	(533)
Non-controlling interests	**(1,785)**	(1,832)
Adjusted amount	**1,235**	1,188

SIGNIFICANT INVESTMENT

As at 30 June 2026, the Group's major investment is the 15.03% equity interests in Sinovac Life Sciences Co., Ltd. ("SINOVAC LS"), a company which is engaged in the R&D, production and sales of human vaccines. The 15.03% equity interest in SINOVAC LS held by the Group was accounted for as "non-current equity investment designated at fair value through other comprehensive income" in the financial statements of the Group as at 30 June 2026. The investment cost was approximately US$515 million (equivalent to approximately RMB3,387.77 million). The fair value of the investment in SINOVAC LS was approximately RMB7,249 million as at 30 June 2026 (31 December 2025: RMB7,529 million), which accounted for approximately 8.7% of total assets of the Group (31 December 2025: 9.9%). No dividend (net of tax) was received from SINOVAC LS during the first half year of 2026 (2025: RMB1,352.70 million (net of tax) was received and was recognised in profit or loss). SINOVAC LS is dedicated to developing innovative vaccines and related biopharmaceutical products and continues to strengthen its R&D and commercialization capabilities in biological medicine technology. The investment in SINOVAC LS has been a great success and the Group may continuously receive potential dividends in the future.

EQUITY INVESTMENTS/FINANCIAL ASSETS DESIGNATED AT FAIR VALUE THROUGH PROFIT OR LOSS AND EQUITY INVESTMENTS DESIGNATED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

As at 30 June 2026, the Group had: 1) non-current equity investments designated at fair value through other comprehensive income (including certain listed and unlisted equity investments such as SINOVAC LS) of approximately RMB8,885.59 million (31 December 2025: approximately RMB9,470.88 million); and 2) current equity investments designated at fair value through profit or loss (including certain listed equity investments) of approximately RMB114.64 million (31 December 2025: approximately RMB219.23 million).

In addition, as at 30 June 2026, the Group had the non-current financial assets at fair value through profit or loss of approximately RMB2,387.02 million (31 December 2025: RMB2,109.09 million) and the current financial assets at fair value through profit or loss, including certain wealth management products of approximately RMB12,543.50 million (31 December 2025: approximately RMB10,146.68 million) and contingent consideration receivables of approximately RMB37.19 million. The wealth management products included CSC Financial (approximately RMB2,593.98 million), Huatai Securities (approximately RMB1,539.89 million), China Galaxy Securities (approximately RMB1,050.00 million), CITIC Securities(approximately RMB780.00 million), CITIC Bank (approximately RMB780.00 million), Guotai Haitong Securities (approximately RMB775.00 million), ICBC (approximately RMB710.00 million) and the wealth management products from other banks. Majority of the wealth management products consisted of principal-guaranteed products with floating return and relatively lower risk of default. All principal and interests will be paid together on the maturity date. The Board of the Company believes that the investment in wealth management products can strengthen the financial position of the Group and bring the fruitful contribution to the profit of the Group. As at 30 June 2026, the above-mentioned wealth management products (approximately RMB12,543.50 million) together with the wealth management products classified in other receivables of RMB Nil (31 December 2025: approximately RMB414.83 million), representing approximately 15.1% of the total assets of the Group.

Each of the transactions of acquisition or disposal of wealth management products as abovementioned was entered into with third party who was not a connected person (as defined in the Rules Governing the Listing of Securities ("Listing Rules") on The Stock Exchange of Hong Kong Limited ("Stock Exchange")) of the Company, and did not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules as all the applicable percentage ratios were less than 5%, calculated either on a standalone basis or by aggregation of the transactions with the same counterparty pursuant to the Rule 14.22 of the Listing Rules.

The Board considers that the investment in equity investments and financial assets can diversify the investment portfolio of the Group and achieve a better return to the Group in the future.

INVESTOR RELATIONS

The Group is committed to maintaining high standards of corporate governance to ensure its long-term sustainable development. It also attaches great importance to communication with shareholders and investors. During the reporting period, the Group actively maintained close and sound contact with a wide range of investors worldwide through different channels to ensure adequate two-way communication. In addition to ensuring that investors had a thorough understanding of its latest business developments and strategies, the Group was also able to gather valuable views from the investment community through interaction with investors to help raise corporate governance practices.

The Group has continued to publish its annual reports, interim reports, disclosures and circulars in a timely manner both on its corporate website and on the website of the Hong Kong Exchanges and Clearing Limited, and also voluntarily issues announcements to inform shareholders and the market of its latest business endeavours, including product approvals, clinical progress, etc., striving to maintain a high level of corporate transparency and enhance market attention.

The Group has also proactively disclosed the latest information on its business development to investors. On 26 March 2026, the Group held its 2025 Annual Results Announcement Conference in Hong Kong, introducing its full-year results and latest business updates. The event was attended by several hundred investors with positive feedback. In addition, the Group issues results press releases in a timely manner to keep retail investors informed of its latest business status and prospects through media channels. In addition to results press releases, the Group also releases information through the media on topics such as the Company's share repurchases and share purchases under its restricted share award scheme, with a view to maintaining a high level of information transparency and strengthening confidence among shareholders and the market.

In addition, the Group participated in many global investment summits and roadshows hosted by major investment banks and securities companies, including Morgan Stanley, Goldman Sachs, UBS, Bank of America, Citi, J.P. Morgan, HSBC, CICC, CITIC, CSC Financial, HTSC during the period. enabling investors to gain insights into its business development and competitive advantages. During the reporting period, the Group participated in more than 400 investor communication meetings in various forms such as one-on-one meetings, group meetings and online calls.

The Group will continue to refine its corporate governance structure and deepen two-way communication with the investment community. Through proactive, comprehensive and efficient investor relations management, the Group will accurately and timely communicate its core competitiveness and long-term value to all sectors of the market.

LIQUIDITY AND FINANCIAL RESOURCES

The Group's liquidity remains strong. During the period, the Group's primary sources of funds were cash derived from operating activities, issuance of panda bonds, and bank borrowings. As at 30 June 2026, the Group's cash and bank balances classified under current assets were approximately RMB14,882.14 million (31 December 2025: approximately RMB12,180.73 million). Bank deposit classified under non-current assets were approximately RMB7,158 million (31 December 2025: approximately RMB10,248 million). The wealth management products classified as financial assets at fair value through profit or loss were approximately RMB12,543.50 million (31 December 2025: approximately RMB10,146.68 million), together with wealth management products classified as other receivables of nil (31 December 2025: approximately RMB414.83 million), the total capital reserves were approximately RMB34,583.64 million (31 December 2025: approximately RMB32,990.24 million). The Group was in a net cash position (including wealth management products) of approximately RMB17,412.19 million (31 December 2025: approximately RMB16,920.23 million), being the aggregate of cash and bank balances classified under current assets, bank deposit classified under non-current assets and wealth management products less the aggregate of short term loans, long term loans and total lease liabilities.

CAPITAL STRUCTURE

As at 30 June 2026, the Group had short term loans of approximately RMB8,669.57 million (31 December 2025: approximately RMB8,395.44 million) and long term loans of approximately RMB8,429.64 million (31 December 2025: approximately RMB7,583.98 million). In addition, total lease liabilities (classified under current and non-current liabilities) amounted to approximately RMB72.23 million as at 30 June 2026 (31 December 2025: RMB90.60 million). As at 30 June 2026, the Group's total available credit facilities amounted to approximately RMB59.8 billion (31 December 2025: approximately RMB63.1 billion) of which RMB42.7 billion were unused (31 December 2025: RMB47.1 billion).

CHARGE ON ASSETS

As at 30 June 2026, the Group had charge on assets of approximately RMB717.20 million (31 December 2025: approximately RMB440.52 million).

CONTINGENT LIABILITIES

As at 30 June 2026, the Group and the Company had no material contingent liabilities (31 December 2025: Nil).

GEARING RATIO

As at 30 June 2026, the total assets of the Group amounted to approximately RMB83,207.72 million (31 December 2025: approximately RMB76,009.82 million) whereas the total liabilities amounted to approximately RMB36,963.01 million (31 December 2025: approximately RMB33,923.89 million). The gearing ratio (total liabilities over total assets) was approximately 44.4% (31 December 2025: approximately 44.6%).

EMPLOYEE AND REMUNERATION POLICIES

The Group had 22,838 employees as at 30 June 2026 and remunerates its employees based on their performance, experience and the prevailing market rates. Other employee benefits include mandatory provident fund, insurance and medical coverage, subsidized training programs as well as employee share incentive schemes. Total staff cost (including Directors' remuneration and equity settled share-based payments) in selling and distribution costs and administrative expenses during the period under review was approximately RMB2,285.49 million (for the six months ended 30 June 2025: approximately RMB2,424.90 million).

The Company adopted a share option scheme on 15 June 2023 (the "2023 Share Option Scheme") and a share award scheme on 5 January 2018 (the "2018 Share Award Scheme"). The Company resolved and approved the implementation of a share incentive scheme by CT Tianqing, a subsidiary, on 7 May 2024 ("2024 CT Tianqing Share Incentive Scheme"). The schemes will provide incentive to retain and encourage the selected participants for the continual operation and development of the Group. For the six months ended 30 June 2026, no option in respect of the shares of the Company ("Shares") had been granted under the 2023 Share Option Scheme, nor any incentive share granted under the 2024 CT Tianqing Share Incentive Scheme, while 146,969 restricted shares (per valuation) were granted and 9,275,200 restricted shares were vested under the 2018 Share Award Scheme; and as at the period end, 525,309,693 Shares were held on trust by a trustee under the 2018 Share Award Scheme and 338,690,000 shares were held on trust by a trustee under the 2024 CT Tianqing Share Incentive Scheme.

EXPOSURE TO FLUCTUATIONS IN EXCHANGE RATES

Most of the assets and liabilities of the Group are denominated in Renminbi, US dollars, Euro, Japanese Yen and HK dollars. The Group has hedged part of the RMB risk in net investments in foreign operations by borrowing RMB loan and will continue to closely monitor the net foreign exchange exposure to reduce the impact of foreign exchange fluctuations.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE ("ESG")

During the first half of the year, in accordance with the overall framework set out in the "Sino Biopharmaceutical Limited ESG Plan (2025–2027)", the Group has continued to advance the close integration of ESG governance and its development strategy. Focus was put on exploring innovative ESG management initiatives while strengthening communication among internal and external stakeholders, and the promotion and dissemination of its ESG values and corporate culture. The Group strives to establish a virtuous cycle of ESG governance characterised by the collaborative participation of internal and external stakeholders.

During the first half of the year, the Group systematically initiated impactful schemes mainly on four key areas: stakeholder engagement, implementation of innovative initiatives, guidance in supply chain responsibility, and fulfilment of social responsibilities. It obtained commendable results in various aspects, including advancement of ESG governance standards, carbon neutrality transition practices, establishment of employee ESG participation model, green supply chain development, and expansion of healthcare accessibility to the general public. These achievements gained broad social recognition, and

won numerous significant awards, among other things, improved ESG ratings from the capital market and professional ESG awards, for the Group. Among more than ten of such awards which include upgrade in MSCI ESG rating to "AA" (industry leader level) for the very first time, the first inclusion in the "2026 Fortune ESG Impact List", being selected for the second consecutive year in S&P Global's "Sustainability Yearbook 2025 (Global Edition)", and was named for the fourth consecutive year in the "S&P Global's Sustainability Yearbook (China Edition)".

Regarding stakeholder engagement, the Group continued to conduct "double materiality assessments" across all business operations. By strengthening the assessment of the impact on financial materiality, it enables a more accurate identification of ESG key material issues to serve as a more effective guidance for the development and implementation of ESG initiatives. Building on this, the Group has further improved its ESG report disclosures for the 2025 financial year. For the third consecutive year, the Group obtained independent third-party assurance of its ESG report from an international professional institute, addressing the concerns of all stakeholders in an accurate, comprehensive and extensive manner.

Regarding innovative ESG governance, the Group has focused on planning its carbon neutrality roadmap, launching energy-saving and carbon-reduction initiatives that is themed "switching from oil to electricity, expanding clean energy and taking low-carbon business travel", while reducing Scope 1, 2 and 3 carbon emissions. In the first half of the year, the Group's carbon emission intensity decreased by 7% year-on-year. The Group organised for the third consecutive year the "ESG DAY of SBP Group", an initiative for fostering ESG culture across the entire workforce. On the day of the event, the Group officially launched the "ESG Knowledge and Action" app, a digital platform for all employees, with integrated functions including teaching, rationalized suggestion collection, and ESG incentive points, for the purpose of establishing a ESG development model which engages the entire workforce. To date, the "ESG Knowledge and Action" app has recorded over 4,000 users.

As for leading supply chain responsibility, building on its previous experience and foundation in responsible supply chain development, the Group became the first in the industry to launch the green supply chain scheme, and formally introduced the "Sino Biopharmaceutical Limited Green Supply Chain Initiative", which covers all key Tier 1 and Tier 2 suppliers. This serves as the basis for the Group to lead the green transition of the supply chain and provides clear guidance for the low-carbon transition to business partners across the supply chain.

As for social responsibility, leveraging its own industrial advantages, the Group continuously advances the accessibility of medicines across the society. In the first half of the year, the Group's core member company, CT Tianqing, donated RMB100 million to the Foundation for the Development of Science and Technology in China in a practical move to support the national "15th Five-Year Plan" strategic framework, contributing to the development of the biopharmaceutical industry as an emerging pillar industry in China, and helped bolster China's high-level scientific and technological self-reliance and self-improvement.

APPRECIATION

On behalf of the Board, I would like to express my gratitude to our shareholders for their trust, support and understanding, as well as to all our staff for their dedication and diligence.

RESULTS

The Board of the Company announces the unaudited interim condensed consolidated results of the Group for the six months ended 30 June 2026 together with the comparative figures for 2025 as follows:

Interim Condensed Consolidated Statement of Profit or Loss

		For the six months ended 30 June	
		2026	2025
	Notes	***RMB'000***	*RMB'000*
		(Unaudited)	(Unaudited)
REVENUE	*3*	**19,444,363**	17,574,778
Cost of sales		**(3,296,638)**	(3,081,084)
Gross profit		**16,147,725**	14,493,694
Other income	*3*	**332,928**	1,686,771
Other gains, net	*3*	**271,337**	626,158
Selling and distribution costs		**(5,260,112)**	(6,449,904)
Administrative expenses		**(969,464)**	(1,093,529)
Research and development costs		**(3,080,029)**	(3,187,558)
Other expenses		**(226,426)**	(354,218)
Financial revenue		***320,479***	*373,576*
Financial cost	*4*	***(169,501)***	*(123,204)*
Net financial income		**150,978**	250,372
Share of profits and losses of associates and joint ventures		**(27,546)**	(4,823)
PROFIT BEFORE TAX	*5*	**7,339,391**	5,966,963
Income tax expense	*6*	**(1,195,921)**	(981,324)
PROFIT FOR THE PERIOD		**6,143,470**	4,985,639
Profit attributable to:			
Owners of the parent		**3,434,598**	3,388,591
Non-controlling interests		**2,708,872**	1,597,048
		6,143,470	4,985,639
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	*8*		
– Basic		**RMB19.10 cents**	RMB18.82 cents
– Diluted		**RMB19.03 cents**	RMB18.80 cents

Details of the interim dividend declared for the period are disclosed in Note 7 of this announcement.

Interim Condensed Consolidated Statement of Comprehensive Income

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
PROFIT FOR THE PERIOD	**6,143,470**	4,985,639
OTHER COMPREHENSIVE INCOME		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences:		
Net loss on hedge of net investment	**(177,114)**	(120,561)
Exchange differences on translation of foreign operations	**(292,929)**	(483,522)
Less: Reclassification adjustments upon deemed partial disposal of an associate	**–**	105
Net other comprehensive income that may be reclassified to profit or loss in subsequent periods	**(470,043)**	(603,978)
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:		
Equity investments designated at fair value through other comprehensive income:		
Changes in fair value	**(129,153)**	(280,856)
Income tax effect	**–**	–
Net other comprehensive income that will not be reclassified to profit or loss in subsequent periods	**(129,153)**	(280,856)
OTHER COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	**(599,196)**	(884,834)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**5,544,274**	4,100,805
Attributable to:		
Owners of the parent	**2,835,430**	2,503,699
Non-controlling interests	**2,708,844**	1,597,106
	5,544,274	4,100,805

Interim Condensed Consolidated Statement of Financial Position

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**8,559,560**	8,699,735
Investment properties		**213,591**	231,666
Right-of-use assets		**1,511,519**	1,533,670
Goodwill		**4,352,631**	3,496,187
Intangible assets		**3,755,081**	3,555,971
Investments in associates and joint ventures		**1,723,918**	1,637,117
Equity investments designated at fair value through other comprehensive income		**8,885,585**	9,470,879
Financial assets at fair value through profit or loss		**2,387,021**	2,109,090
Bank deposits		**7,158,000**	10,248,000
Deferred tax assets		**581,000**	506,585
Prepayments and other assets		**40,384**	55,847
Total non-current assets		**39,168,290**	41,544,747
CURRENT ASSETS			
Inventories		**1,968,246**	2,256,663
Trade and bills receivables	*9*	**10,676,350**	6,263,587
Prepayments, other receivables and other assets		**3,351,893**	3,021,784
Amounts due from related companies		**465,482**	376,400
Equity investments designated at fair value through profit or loss		**114,637**	219,232
Financial assets at fair value through profit or loss		**12,580,685**	10,146,679
Cash and bank balances	*10*	**14,882,137**	12,180,729
Total current assets		**44,039,430**	34,465,074
CURRENT LIABILITIES			
Trade and bills payables	*11*	**2,166,008**	1,497,288
Tax payable		**706,017**	696,154
Other payables and accruals		**15,253,125**	14,523,669
Interest-bearing bank borrowings		**8,669,570**	8,395,435
Amounts due to related companies		**200,975**	47,019
Lease liabilities		**11,385**	23,287
Contingent consideration		**16,470**	16,717
Total current liabilities		**27,023,550**	25,199,569
NET CURRENT ASSETS		**17,015,880**	9,265,505
TOTAL ASSETS LESS CURRENT LIABILITIES		**56,184,170**	50,810,252

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
TOTAL ASSETS LESS CURRENT LIABILITIES		**56,184,170**	50,810,252
NON-CURRENT LIABILITIES			
Deferred government grants		**695,064**	621,875
Interest-bearing bank borrowings		**8,429,642**	7,583,979
Lease liabilities		**60,844**	67,310
Contingent consideration		**200,988**	164,759
Deferred tax liabilities		**552,917**	286,402
Total non-current liabilities		**9,939,455**	8,724,325
Net assets		**46,244,715**	42,085,927
EQUITY			
Equity attributable to owners of the parent			
Share capital	*12*	**412,469**	413,669
Treasury shares		**(2,961,178)**	(2,951,211)
Reserves		**35,116,790**	33,208,500
		32,568,081	30,670,958
Non-controlling interests		**13,676,634**	11,414,969
Total equity		**46,244,715**	42,085,927

Notes:

1. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with HKAS 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

1.2 CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the condensed consolidated financial statements for the six months ended 30 June 2026 are consistent with those presented in the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the new and revised standards mandatorily effective during the current interim period. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

In the current interim period, the Group has applied the following new and amendments to HKFRS Accounting Standards issued by the HKICPA, for the first time, which are mandatorily effective for the Group's annual period beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7 (Revised) *The contracts referencing nature-dependent electricity*

Amendments to HKFRS 9 and HKFRS 7 (Revised) *Classification and measurement of financial instruments*

Annual improvements to HKFRS Accounting Standards – Volume 11

The application of these amendments to HKFRS Accounting Standards that are effective from 1 January 2026 did not have any significant impact on the Group's financial positions and performance for the current and prior periods and on the disclosures set out in these condensed consolidated financial statements. The Group has not early adopted any new standard, interpretation or amendment that has been issued but is not yet effective for the current accounting period.

2. OPERATING SEGMENT INFORMATION

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker ("CODM"). The Group's business activities, for which discrete financial statements are available, are reviewed and evaluated by CODM. CODM, who is responsible for allocating resources and regularly assessing performance of the operating segment, has been identified as the executive directors of the Company that make strategic decisions.

During 2025, CODM has reorganized the structure of internal reporting in a manner that causes the composition of the Group's reportable operating segment to change. In order to provide more relevant accounting information in the financial report that is reflective of the current business management structure of the Group, the Company has decided to adjust the presentation of its operating segments.

Before the change in segment reporting, the Group had three business segments, including patent medicines, investment and others. After the reorganization, the Group has one reportable operating segment as the CODM monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. This change does not affect the financial statement information disclosures and presentation, and it only affects the presentation of segment year's reporting. Previous year segment disclosures have been re-presented to conform with the current year's presentation.

Given after the change, there is only one reportable segment, so no operating segment information was presented.

Information about geographical areas

Since over 90% of the Group's revenue were generated from the sale of pharmaceutical products in Chinese Mainland and most of the Group's identifiable operating assets and liabilities were located in Chinese Mainland, no geographical segment information in accordance with HKFRS 8 Operating Segments is presented.

Information about a major customer

No information about major customers is presented as no single customer contributed to over 10% or more of the Group's revenue for the six months ended 30 June 2026 and 2025, and hence no major customer information is presented.

3. REVENUE, OTHER INCOME AND OTHER GAINS, NET

Revenue represents the net invoiced value of goods or services sold, after allowances for returns and trade discounts.

An analysis of revenue, other income and other gains, net is as follows:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue from contracts with customers		
Sale of industrial products	**18,221,818**	17,248,391
Revenue from out-licensing	**975,356**	44,297
Revenue from other sources	**247,189**	282,090
	19,444,363	17,574,778

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other income		
Dividend income	**70,778**	1,503,660
Government grants	**27,009**	26,732
Sale of scrap materials	**2,794**	1,272
Investment income	**108,872**	102,034
Total rental income	**8,024**	3,028
Additional value-added tax credit	**26,697**	10,627
Others	**88,754**	39,418
	332,928	1,686,771

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Other gains, net		
Gain on disposal of items of property, plant and equipment	**1,523**	1,019
Gain on deemed partial disposal of an associate	**1,124**	352
Fair value gains/(losses), net		
Equity investments designated at fair value through profit or loss	**150,687**	(16,112)
Financial assets at fair value through profit or loss	**13,531**	9,917
Financial assets at fair value through profit or loss (non-current)	**36,012**	541,479
Contingent consideration	**25,840**	–
Exchange gains, net	**42,620**	89,503
	271,337	626,158

4. FINANCE COSTS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Interest on bank borrowings	**168,356**	121,160
Interest on convertible bonds	**–**	46
Interest on lease liabilities	**1,145**	1,998
	169,501	123,204

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold	**3,296,638**	3,081,084
Depreciation of property, plant and equipment	**400,195**	431,830
Depreciation of investment properties	**13,402**	13,947
Depreciation of right-of-use assets	**26,246**	45,795
Amortization of intangible assets	**105,670**	84,120
Research and development costs	**3,080,029**	3,187,558
Loss on disposal of items of property, plant and equipment	**(1,523)**	(1,019)
Gain on deemed partial disposal of an associate	**(1,124)**	(352)
Share of results of associates and joint venture	**27,546**	4,823
Bank interest income	**(320,479)**	(373,576)
Dividend income	**(70,778)**	(1,503,660)
Investment income	**(108,872)**	(102,034)
Fair value (gains)/losses, net:		
Equity investments designated at fair value through profit or loss	**(150,687)**	16,112
Financial assets at fair value through profit or loss	**(13,531)**	(9,917)
Financial assets at fair value through profit or loss (Non-current)	**(36,012)**	(541,479)
Contingent consideration	**(25,840)**	–
Auditors' remuneration	**3,733**	3,565
Staff costs (including directors' remuneration) in selling and distribution costs and administrative expenses:		
Wages and salaries	**1,785,263**	1,918,241
Pension scheme contributions	**415,297**	448,029
Equity settled share based payments	**84,931**	58,628
	2,285,491	2,424,898
Exchange difference, net	**(42,620)**	(89,503)
Impairment loss on Trade Receivables	**32,311**	24,616
Impairment loss on Other Receivables (Reversal)/Loss	**(4,857)**	211,273

6. INCOME TAX

Taxes on profits have been calculated at the rates of tax prevailing in the jurisdictions in which the Group operates.

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Group:		
Current – Hong Kong	**–**	–
Current – Mainland China	**1,127,969**	816,512
Deferred tax	**67,952**	164,812
Total tax charge for the period	**1,195,921**	981,324

The Company incorporated in the Cayman Islands is not subject to tax on income or capital gains under the law of the Cayman Islands. In addition, dividend payments are not subject to withholding tax in the Cayman Islands.

The subsidiaries incorporated in the British Virgin Islands (the "BVI") are not subject to income tax as these subsidiaries do not have a place of business (other than a registered office only) or carry on any business in the BVI.

The subsidiaries incorporated in Hong Kong is subject to Hong Kong profits tax at the rate of 16.5% (2025: 16.5%) on the estimated assessable profits arising in Hong Kong during the period.

The subsidiary incorporated in the United Kingdom ("UK") is subject to UK Corporate Income Tax at a rate of 25% (2025: 25%) on the estimated assessable profits arising in the UK during the period.

Belgium profits tax has been provided at a rate of 25% (2025: 25%) on the estimated assessable profits arising in Belgium during the period.

The provision for corporate income tax in Mainland China is based on the statutory rate of 25% of the assessable profits as determined in accordance with the PRC Corporate Income Tax Law which was approved and became effective on 1 January 2008.

Certain subsidiaries operating in Mainland China were entitled to a preferential corporate income tax rate of 15% during the period because they were qualified as "High and New Technology Enterprises".

Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. The requirement is effective from 1 January 2008 and applies to earnings after 31 December 2007. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. The Group is therefore liable to withholding taxes on dividends distributed by subsidiaries and associates established in Mainland China in respect of earnings generated from 1 January 2008 with 5% and 10%, respectively.

Pillar Two income taxes

The Group is within the scope of the Pillar Two model rules. The Group has applied the mandatory exception to recognising and disclosing information about deferred tax assets and liabilities arising from Pillar Two income taxes, and will account for the Pillar Two income taxes as current tax when incurred. Pillar Two legislation has been enacted or substantially enacted and in effect as at 30 June 2026 in certain jurisdictions in which the Group operates, including Hong Kong, United Kingdoms, Belgium and Spain.

Pillar Two legislation was gazetted in Hong Kong on 6 June 2025, the jurisdiction in which the Company is listed, and has come into effect retroactively from 1 January 2025. Under the legislation, the Group may be liable to pay a top-up tax for the difference between its GloBE effective tax rate per jurisdiction and the 15% minimum rate. The Group has not been subject to material current income tax exposure under the Pillar Two regime as of 30 June 2026 according to the assessment. The Group will continue to monitor the Pillar Two developments and reassess the potential impact on its tax position.

7. DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cash dividends to the ordinary equity holders of the parent:		
Dividends on ordinary shares declared and payable:		
Final dividend for 2025: HK5 cents per share (2024: HK4 cents per share)	**782,228**	667,011
Proposed dividends on ordinary shares:		
Interim dividend for 2026: HK7 cents per share (2025: HK5 cents per share)	**1,079,376**	835,638

The proposed dividends on ordinary shares are not recognised as a liability as at 30 June 2026.

The Board has declared the payment of an interim dividend of HK7 cents per ordinary share for the six months ended 30 June 2026 (2025: HK5 cents). The 2026 interim dividend will be paid to shareholders on Thursday, 24 September 2026 whose names appear on the register of members of the Company on Friday, 4 September 2026. For the purpose of determining shareholders' entitlement to the interim dividend, the register of members of the Company will be closed from Thursday, 3 September 2026 to Friday, 4 September 2026, both days inclusive, during which period no transfer of shares will be effected. In order to qualify for the interim dividend, all transfers accompanied by the relevant share certificates must be lodged with the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by 4:30 p.m. on Wednesday, 2 September 2026.

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amount is based on the profit attributable to ordinary equity holders of the parent for the period of approximately RMB3,434,598,000 (2025: approximately RMB3,388,591,000), and the weighted average number of ordinary shares of 17,983,011,615 (2025: 18,003,635,574) in issue during the period.

The calculation of the diluted earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent, adjusted to reflect the interest, exchange difference and fair value change on the convertible bonds, where applicable (see below). The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise or conversion of all dilutive potential ordinary shares into ordinary shares.

The computation of diluted earnings per share for the six months period ended 30 June 2026 and 2025 assumes the exercise of the Company's equity settled restricted shares granted pursuant to the launch of 2024 CT Tianqing Share Incentive Scheme as the exercise price (including the fair value of services yet to be rendered) of the restricted shares was lower than the average market price for the shares during the outstanding period.

For the six months ended 30 June 2026, the calculation of diluted earnings per share assumed the future issuance of shares by the Company as part of the consideration for the acquisition of subsidiary Hygieia pursuant to the agreement entered into in connection with the acquisition of Hygieia.

The diluted earnings per share for the period ended 30 June 2025 did not assume conversion of the convertible bonds as its conversion would be anti-dilutive.

The calculations of basic and diluted earnings per share for the six months period ended 30 June 2026 are based on:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Earnings		
Profit attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	**3,434,598**	3,388,591
Profit attributable to ordinary equity holders of the parent before interest on convertible bonds	**3,434,598**	3,388,591
Share of profit	**3,434,598**	3,388,591

	No. of shares	
	For the six months ended 30 June	
	2026	2025
	(Unaudited)	(Unaudited)
Shares		
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	**17,983,011,615**	18,003,635,574
Effect of dilution weighted average number of ordinary shares:		
– Equity settled share-based payments	**59,352,263**	22,239,128
– Potential issue of consideration shares related acquisition of a subsidiary	**7,298,161**	–
	18,049,662,039	18,025,874,702

9. TRADE AND BILLS RECEIVABLES

An ageing analysis of the Group's trade and bills receivables as at the end of reporting period, based on invoice date and net of provisions, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Current to 90 days	**10,167,130**	5,173,413
91 days to 180 days	**136,515**	736,324
Over 180 days	**372,705**	353,850
	10,676,350	6,263,587

10. CASH AND BANK BALANCES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Cash and bank balances, unrestricted	**10,106,350**	4,616,897
Time deposits with original maturity of less than three months	**2,017,878**	2,767,998
Time deposits with original maturity of more than three months	**2,757,909**	4,795,834
Cash and bank balances	**14,882,137**	12,180,729

11. TRADE AND BILLS PAYABLES

An ageing analysis of the Group's trade and bills payables as at the end of reporting period, based on invoice date, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Current to 90 days	**1,250,949**	1,010,073
91 days to 180 days	**206,349**	195,423
Over 180 days	**708,710**	291,792
	2,166,008	1,497,288

12. SHARE CAPITAL

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Issued and fully paid:		
18,705,017,230 ordinary shares of approximately HK$0.025 each (2025: 18,760,717,230 ordinary shares of approximately HK$0.025 each)	**412,469**	413,669

13. Business Combination

Acquisition of Hangzhou Hygieia Biopharmaceutical Co., Limited ("Hygieia")

On 13 January 2026, the Group acquired Hygieia as a wholly-owned subsidiary. The Group entered into a sale and purchase agreement with the vendor, founders, Hygieia and its subsidiaries in Guangzhou, Xiamen and Shanghai. Pursuant to the agreement, the vendor conditionally agreed to sell and the purchaser conditionally agreed to acquire 100% equity interest in Hygieia. The maximum base consideration amounts to RMB1,200,000,000 (subject to downward adjustment), payable partly in cash and partly by way of consideration shares. Subsequent to the completion date at the end of March 2026, Hygieia became an indirect wholly-owned subsidiary of the Company.

The fair values of the identifiable assets and liabilities of Hygieia as at the date of acquisition were as follows:

	Fair value recognised on acquisition *RMB'000*
Property, plant and equipment	11,571
Intangible assets	103,649
Right-of-use assets	3,632
Long-term prepayments	984
Cash and bank balances	43,832
Inventories	1,121
Trade receivable	300,000
Prepayments, other receivables and other assets	5,375
Trade payables	(84,811)
Other payables and accrued expenses	(16,825)
Interest-bearing bank borrowings	(20,000)
Deferred tax liabilities	(15,669)
Lease liabilities	(3,415)
Deferred income	(1,500)
Total identifiable net assets at fair value	327,944
Goodwill arising on acquisition	872,056
	1,200,000
Consideration settled as follows:	
Cash	1,041,370
Contingent consideration	71,179
New shares to be issued	87,451
	1,200,000

Analysis of cash flows in respect of the acquisition is as follows:	*RMB'000*
Cash consideration paid	1,041,370
Cash and bank balances acquired	(43,832)
Net outflow of cash and cash equivalents included in cash flows from investing activities	997,538
Total net outflow	997,538

FURTHER INFORMATION IN RELATION TO THE 2025 ANNUAL REPORT

Reference is made to the annual report of Sino Biopharmaceutical Limited (the "**Company**") for the year ended 31 December 2025 (the "**2025 Annual Report**"). The Company would like to provide additional information as follows:

2023 Share Option Scheme

The total number of shares available for issue under the 2023 Share Option Scheme

As set out in the 2025 Annual Report, no share option has been granted under the 2023 Share Option Scheme since its adoption.

The number of options available for grant under the scheme mandate and the service provider sublimit (if applicable) as at 1 January 2025 and 31 December 2025 under the 2023 Share Option Scheme and any other schemes was 1,880,921,723 Shares, representing approximately 10% of the issued share capital of the Company on the date of approval of the 2023 Share Option Scheme on 15 June 2023, and the service provider sublimit as at 1 January 2025 and 31 December 2025 was 188,092,172 Shares, representing approximately 1% of the total number of Shares in issue on the date of approval of the 2023 Share Option Scheme.

The total number of shares available for issue under the 2023 Share Option Scheme was 1,880,921,723 Shares, representing approximately 10.03% of the issued Shares (excluding treasury shares) as at the date of the 2025 Annual Report.

Maximum entitlement of each Eligible Participant

Where any grant of an Option to an Eligible Participant would result in the Shares issued and to be issued in respect of all options and awards granted to such Eligible Participant (excluding any options and awards lapsed in accordance with the terms of the relevant schemes) in the twelve(12)–month period up to and including the date of such grant representing in aggregate exceeding 1% of the Shares in issue, such grant must be separately approved by the Shareholders in a general meeting of the Company with such Eligible Participant and the person's close associates (or associates if the Eligible Participant is a connected person) abstaining from voting.

Period within which the share options may be exercised

The period within which the share options may be exercised by the grantees is to be determined and notified by the Company to the grantee at the time of making an offer provided that such period shall not go beyond the day immediately prior to the tenth (10th) anniversary of the offer date with respect to the relevant share option.

Vesting period

Save for the circumstances prescribed in the terms of the 2023 Share Option Scheme for Employee Participants, a share option must be held by the grantee for a period that is not shorter than the minimum period (a period of twelve (12) months commencing on the offer date) (the "**Minimum Period**") before the share option can be exercised.

In relation to Employee Participants only, the Board may at its discretion grant Options with a vesting period shorter than the Minimum Period in the following circumstances:

(1) grants of "**make-whole**" Options to new joiners to replace the share options they

forfeited when leaving the previous employers;

(2) grants to an Eligible Participant whose employment is terminated due to death or

occurrence of any out of control event;

(3) grants that are made in batches during a year for administrative and compliance reasons, which include Options that should have been granted earlier if not for such administrative or compliance reasons but had to wait for subsequent batch;

(4) grants of Options with a mixed or accelerated vesting schedule such as where the

Options may vest evenly over a period of twelve (12) months; or

(5) grants with performance-based vesting conditions in lieu of time-based vesting criteria.

The amount payable on application or acceptance of the share options and the period within which payment must be paid

An Offer shall remain open for acceptance by the Eligible Participant concerned (and by no other person, including the Eligible Participant's personal representative) for a period of twenty-one (21) days from the date of offer.

An Offer shall be deemed to have been accepted by an Eligible Participant concerned in respect of all the Shares which are offered to such Eligible Participant when the duplicate letter comprising acceptance of the Offer duly signed by the Eligible Participant, together with a payment in favour of the Company of HK$1.00 as consideration for the grant thereof, is received by the Company.

Basis of determining the exercise price

The subscription price for Shares to be subscribed under the 2023 Share Option Scheme may be determined by the Board at its absolute discretion, provided that it shall not be less than the highest of: (1) the closing price of the Shares as shown in the daily quotations sheet of the Stock Exchange on the offer date, which must be a Business Day; (2) the average of the closing prices of the Shares as shown in the daily quotations sheets of the Stock Exchange for the five (5) consecutive days on which the Shares are traded on the Stock Exchange immediately preceding the offer date; and (3) the nominal value of the Share on the offer date.

Remaining life of the 2023 Share Option Scheme

The 2023 Share Option Scheme was adopted on 15 June 2023 and shall be valid and effective until 14 June 2033, being the date which falls on the date immediately prior to the tenth anniversary of such date, unless terminated earlier in accordance of the terms of the 2023 Share Option Scheme. The remaining life of the ESOP as at the date of the 2025 Annual Report is approximately seven years and three months.

2024 CT Tianqing Share Incentive Scheme

On 7 May 2024, the board of directors of the Company resolved and approved the implementation of a share incentive scheme (the "**2024 CT Tianqing Share Incentive Scheme**") by CT Tianqing, a subsidiary of the Company, to motivate core talents who would play an important role in the future operations and development of CT Tianqing.

The incentive Shares granted under the 2024 CT Tianqing Share Incentive Scheme to the Selected Participants will be vested by phases after the Selected Participants have passed their performance appraisals.

Profit Undertakings

References are made to the announcements of the Company dated 30 October 2024 and 18 November 2024 in relation to, among other things, the acquisition of 29.99% equity interest and the possible voluntary partial offer to acquire a maximum of 25.01% equity interest in Hob Biotech Group Corp., Ltd. (江蘇浩歐博生物醫藥股份有限公司) (the "**Announcements**"). Unless otherwise defined herein, capitalised terms used in this section shall have the same meanings as those defined in the Announcements.

As set out in the Announcements, upon completion of the Equity Transfer, Hob Biotech HK undertook that (i) the Target Company's net profit attributable to shareholders of parent company shall be no less than RMB49.70 million, RMB52.18 million and RMB54.79 million for the financial years 2024, 2025 and 2026, respectively; and (ii) the Target Company's net profit attributable to shareholders of parent company after deducting extraordinary gains and losses shall be no less than RMB45.47 million, RMB47.74 million and RMB50.13 million for the financial years 2024, 2025 and 2026, respectively (collectively, the "**Profit Undertakings**").

Based on the audited financial statements of the Target Company for the two years ended 31 December 2024 and 2025, the Profit Undertaking was met in respect of the year ended 31 December 2024, but the Profit Undertaking was not met in respect of the year ended 31 December 2025, details of which are as follows:

Profit Undertakings *(Note)*	**Year ended 31 December 2024**	**Year ended 31 December 2025**
Profit Undertaking – the Target Company's net profit attributable to shareholders of parent company	RMB49.70 million	RMB52.18 million
Actual net profit attributable to shareholders of parent company	RMB53.09 million	RMB49.85 million
Profit Undertaking – the Target Company's net profit attributable to shareholders of parent company after deducting extraordinary gains and losses	RMB45.47 million	RMB47.74 million
Actual net profit attributable to shareholders of parent company after deducting extraordinary gains and losses	RMB52.26 million	RMB41.32 million

Note: Pursuant to the Equity Transfer Agreement, the Target Company's net profit attributable to shareholders of parent company and the Target Company's net profit attributable to shareholders of parent company after deducting extraordinary gains and losses shall be determined on the basis of the China Accounting Standards for Business Enterprises and shall exclude the financial effects attributable to (i) the Target Company's anti-allergy medicines business; (ii) the new businesses carried out by the Target Company subsequent to Beijing Runkang obtaining control of the Target Company; and (iii) the share incentive schemes of the relevant personnel in connection with such new businesses (collectively, the "Profits").

As the Profit Undertakings in the year ended 31 December 2025 was not met, Hob Biotech HK was required to compensate, and had so compensated, the Target Company for such financial year by way of cash payment in the amount of RMB6,415,417, being the higher of (i) the shortfall between the Target Company's actual net profit/loss attributable to shareholders of parent company stated in the special audit report for such financial year and the required net profit under the Profit Undertakings; and (ii) the shortfall between the Target Company's actual net profit/loss attributable to shareholders of parent company after deducting extraordinary gains and losses stated in the special audit report for such financial year and the required net profit under the Profit Undertakings.

The Company will comply with the relevant disclosure requirement under Rule 14A.63 of the Listing Rules, in particular where there is any subsequent change to the Profit Undertakings or the actual performance of the Profit Undertakings for the year ending 31 December 2026 fails to meet the requirements stated in the Equity Transfer Agreement.

CORPORATE GOVERNANCE CODE

In the opinion of the Directors, the Company has complied with all the Code Provisions of the Corporate Governance Code as set out in Appendix C1 to the Listing Rules for the six months ended 30 June 2026 except for the deviation from Code Provision C.1.5 in relation to attendance of the annual general meeting of the Company (the "AGM") by the independent non-executive Directors ("INEDs") of the Company. One INED was unable to attend the AGM held on 17 June 2026 due to other business engagements.

INDEPENDENT NON-EXECUTIVE DIRECTORS, AUDIT COMMITTEE AND REVIEW OF RESULTS

During the six months ended 30 June 2026, the Company has complied with Rules 3.10 and 3.10(A) of the Listing Rules and has appointed sufficient number of INEDs including two with appropriate professional qualifications, or accounting or related financial management expertise. The Audit Committee is comprised of five INEDs. It has reviewed with management the accounting principles and practices adopted by the Group and discussed internal control and financial reporting matters including the review of the unaudited consolidated financial statements of the Company for the period under review.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the six months ended 30 June 2026, the Company bought back a total of 77,765,000 Shares on the Stock Exchange at an aggregate consideration of approximately HK$408,959,196 before expenses.

Among the bought back Shares, 55,700,000 shares were cancelled during the reporting period. The remaining 22,065,000 shares repurchased during the reporting period were cancelled in July 2026. Further details are set out as follows:

Month	Number of Shares bought back	Purchase consideration per Share		Consideration paid
		Highest	Lowest	
		HK$	*HK$*	*HK$*
March	15,350,000	5.89	5.81	89,861,670
April	16,170,000	5.84	5.41	90,366,775
May	24,180,000	5.65	5.16	130,387,047
June	22,065,000	4.69	4.23	98,343,704

Pursuant to the rules of the 2018 Share Award Scheme, the trustee of the scheme purchased on the Stock Exchange a total of 4,650,000 Shares at a total consideration of approximately HK$27,348,330 during the period.

No shares were purchased by the trustee on the Stock Exchange under the 2024 CT Tianqing Share Incentive Scheme during the period.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the period.

FORWARD LOOKING STATEMENTS

Certain statements contained in this announcement may be viewed as "forward-looking statements" with respect to the business outlook, financial performance estimates, and business operations forecast of the Group. These forward-looking statements are based on the current beliefs, assumptions, and expectations of and the information currently available to the Board and the Company, and therefore involve risks and uncertainties. Actual outcome may differ materially from the forecasts and expectations in such forward-looking statements. The Company assumes no obligation to update the forward-looking statements contained in this announcement. In light of the above risks and uncertainties, shareholders of the Company and potential investors should not place undue reliance on such statements.

By Order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 19 August 2026

As at the date of this announcement, the Board of the Company comprises five executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y and Mr. Tse Hsin, and six independent non-executive directors, namely Mr. Lu Zhengfei, Ms. Lu Hong, Mr. Zhang Lu Fu, Dr. Li Kwok Tung Donald, Dr. Chen Lieping and Dr. Lu Bai.